News list for " malignant"

CureX announces the start of using business revenue to buy back and destroy CUX tokens

On January 23rd, CureX recently announced that 20% of the sales of its TRC-T products for the treatment of malignant synovial sarcoma will be used to buy back CUX and destroy it. This operation marks CureX's further strengthening of the value and market stability of CUX tokens while promoting the application of its biotech products. In the first round of repurchases, CureX purchased 100 SOL and destroyed 4259,993 CUX tokens. CureX promises to continue to use a portion of its product revenue to b...

clock
2025-01-23 10:16:50
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.